Stefan Schönland

13.1k total citations · 2 hit papers
222 papers, 7.2k citations indexed

About

Stefan Schönland is a scholar working on Molecular Biology, Hematology and Genetics. According to data from OpenAlex, Stefan Schönland has authored 222 papers receiving a total of 7.2k indexed citations (citations by other indexed papers that have themselves been cited), including 185 papers in Molecular Biology, 79 papers in Hematology and 48 papers in Genetics. Recurrent topics in Stefan Schönland's work include Amyloidosis: Diagnosis, Treatment, Outcomes (169 papers), Multiple Myeloma Research and Treatments (52 papers) and Parathyroid Disorders and Treatments (24 papers). Stefan Schönland is often cited by papers focused on Amyloidosis: Diagnosis, Treatment, Outcomes (169 papers), Multiple Myeloma Research and Treatments (52 papers) and Parathyroid Disorders and Treatments (24 papers). Stefan Schönland collaborates with scholars based in Germany, United States and Italy. Stefan Schönland's co-authors include Ute Hegenbart, Giampaolo Merlini, Giovanni Palladini, Anthony D. Ho, Arnt V. Kristen, Philip N. Hawkins, Hartmut Goldschmidt, Christoph Kimmich, Morie A. Gertz and Angela Dispenzieri and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Angewandte Chemie International Edition.

In The Last Decade

Stefan Schönland

208 papers receiving 7.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes

2012 625 citations Giovanni Palladini, Angela Dispenzieri et al. Journal of Clinical Oncology profile →
Systemic immunoglobulin light chain amyloidosis

2018 338 citations Giampaolo Merlini, Angela Dispenzieri et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stefan Schönland Germany	43	5.9k	1.6k	1.5k	1.5k	1.4k	222	7.2k
Laura Obici Italy	53	8.1k 1.4×	1.3k 0.8×	1.7k 1.1×	799 0.5×	1.8k 1.3×	181	9.0k
Ute Hegenbart Germany	51	5.8k 1.0×	2.0k 1.2×	2.1k 1.4×	4.1k 2.7×	1.3k 0.9×	281	9.5k
Ashutosh Wechalekar United Kingdom	55	9.3k 1.6×	2.3k 1.4×	2.2k 1.5×	1.5k 1.0×	3.2k 2.3×	267	10.5k
Julian D. Gillmore United Kingdom	61	11.9k 2.0×	1.9k 1.2×	2.7k 1.8×	1.1k 0.7×	4.1k 2.9×	330	13.4k
Francis K. Buadi United States	57	8.7k 1.5×	2.3k 1.4×	4.8k 3.2×	7.8k 5.2×	1.1k 0.8×	398	12.5k
Jason D. Theis United States	38	3.3k 0.6×	388 0.2×	697 0.5×	348 0.2×	1.6k 1.2×	93	4.0k
Janet A. Gilbertson United Kingdom	31	3.9k 0.7×	361 0.2×	1.1k 0.7×	170 0.1×	1.6k 1.2×	96	4.7k
Michaela Liedtke United States	36	2.5k 0.4×	624 0.4×	2.1k 1.4×	1.7k 1.1×	294 0.2×	167	5.0k
Jan Voorberg Netherlands	41	1.7k 0.3×	1.2k 0.7×	284 0.2×	3.8k 2.6×	565 0.4×	202	6.6k
Junya Kuroda Japan	34	2.0k 0.3×	707 0.4×	1.5k 1.0×	1.3k 0.8×	100 0.1×	217	4.7k

Countries citing papers authored by Stefan Schönland

Since Specialization

Citations

This map shows the geographic impact of Stefan Schönland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stefan Schönland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stefan Schönland more than expected).

Fields of papers citing papers by Stefan Schönland

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stefan Schönland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stefan Schönland. The network helps show where Stefan Schönland may publish in the future.

Co-authorship network of co-authors of Stefan Schönland

This figure shows the co-authorship network connecting the top 25 collaborators of Stefan Schönland. A scholar is included among the top collaborators of Stefan Schönland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stefan Schönland. Stefan Schönland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Weberling, Lukas D., Andreas Ochs, Mitchel Benovoy, et al.. (2025). Machine Learning to Automatically Differentiate Hypertrophic Cardiomyopathy, Cardiac Light Chain, and Cardiac Transthyretin Amyloidosis: A Multicenter CMR Study. Circulation Cardiovascular Imaging. 18(7). e017761–e017761. 2 indexed citations

Hegenbart, Ute, Stefan Schönland, Jan Purrucker, et al.. (2024). T2-relaxometry in a large cohort of hereditary transthyretin amyloidosis with polyneuropathy. Amyloid. 31(4). 309–317.

Kastritis, Efstathios, Giovanni Palladini, Meletios Α. Dimopoulos, et al.. (2024). Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: An Updated Analysis of a Phase 2 Study By the European Myeloma Network. Blood. 144(Supplement 1). 1927–1927.

Kühn, Lukas C., Christian Haupt, Sebastian Wiese, et al.. (2024). Cryo-EM structure of a lysozyme-derived amyloid fibril from hereditary amyloidosis. Nature Communications. 15(1). 9648–9648. 4 indexed citations

John, Lukas, Sandra Sauer, Ute Hegenbart, et al.. (2023). Idecabtagene Vicleucel Is Well Tolerated and Effective in Relapsed/Refractory Myeloma Patients with Prior Allogeneic Stem Cell Transplantation. Transplantation and Cellular Therapy. 29(10). 609.e1–609.e6. 4 indexed citations

Gertz, Morie A., Adam D. Cohen, Raymond L. Comenzo, et al.. (2023). P56 SURVIVAL BENEFIT OF BIRTAMIMAB IN MAYO STAGE IV AL AMYLOIDOSIS IN THE PHASE 3 VITAL STUDY WAS CONSISTENT ACROSS ALL KEY BASELINE VARIABLES. HemaSphere. 7(S2). 41–42. 1 indexed citations

Dittrich, Tobias, Martin Schorb, Niels Weinhold, et al.. (2023). High-throughput electron tomography identifies centriole over-elongation as an early event in plasma cell disorders. Leukemia. 37(12). 2468–2478. 2 indexed citations

Poos, Alexandra M., Marc S. Raab, Hartmut Goldschmidt, et al.. (2023). Comparison of IGLV2‐14 light chain sequences of patients with AL amyloidosis or multiple myeloma. FEBS Journal. 290(17). 4256–4267. 2 indexed citations

Granzow, Martin, et al.. (2022). Analysis of the complete lambda light chain germline usage in patients with AL amyloidosis and dominant heart or kidney involvement. PLoS ONE. 17(2). e0264407–e0264407. 13 indexed citations

10.

Baur, Julian, et al.. (2022). Cryo-EM structure of an ATTRwt amyloid fibril from systemic non-hereditary transthyretin amyloidosis. Nature Communications. 13(1). 6398–6398. 27 indexed citations

11.

Wechalekar, Ashutosh, María Teresa Cibeira, Simon Gibbs, et al.. (2022). Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group. Amyloid. 30(1). 3–17. 46 indexed citations

12.

Radamaker, Lynn, Julian Baur, Matthias Neumann, et al.. (2021). Role of mutations and post-translational modifications in systemic AL amyloidosis studied by cryo-EM. Nature Communications. 12(1). 6434–6434. 56 indexed citations

13.

Ungerer, Matthias N., Ernst Hund, Jan Purrucker, et al.. (2020). Real-world outcomes in non-endemic hereditary transthyretin amyloidosis with polyneuropathy: a 20-year German single-referral centre experience. Amyloid. 28(2). 91–99. 12 indexed citations

14.

Kimmich, Christoph, Tobias Terzer, Axel Benner, et al.. (2020). Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria. Blood. 135(18). 1517–1530. 61 indexed citations

15.

Kazman, Pamina, Benedikt Weber, Ute Hegenbart, et al.. (2020). Fatal amyloid formation in a patient’s antibody light chain is caused by a single point mutation. eLife. 9. 42 indexed citations

16.

Minnema, Monique C., Kazem Nasserinejad, Bouke P. C. Hazenberg, et al.. (2019). Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial. Haematologica. 104(11). 2274–2282. 23 indexed citations

17.

Sanchorawala, Vaishali, Giovanni Palladini, Vishal Kukreti, et al.. (2017). A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood. 130(5). 597–605. 101 indexed citations

18.

Minnema, Monique C., Kazem Nasserinejad, Bouke P. C. Hazenberg, et al.. (2017). HOVON 104; FINAL RESULTS FROM A MULTICENTER, PROSPECTIVE PHASE II STUDY OF BORTEZOMIB BASED INDUCTION TREATMENT FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH DE NOVO AL AMYLOIDOSIS. Data Archiving and Networked Services (DANS). 1 indexed citations

19.

Gertz, Morie A., Heather Landau, Raymond L. Comenzo, et al.. (2016). First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction. Journal of Clinical Oncology. 34(10). 1097–1103. 147 indexed citations

20.

Meijer, Jiska, Stefan Schönland, Giovanni Palladini, et al.. (2008). Sjögren's syndrome and localized nodular cutaneous amyloidosis: Coincidence or a distinct clinical entity?. Arthritis & Rheumatism. 58(7). 1992–1999. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact